CMPS · COMPASS Pathways

The thesis

Compass Pathways is modestly more likely to beat the S&P 500 over the next three months. It completed the New Drug Application (NDA) for its psilocybin treatment COMP360 on 9 November 2026, which starts a priority-voucher review with a company-cited target of one to two months. The FDA's acceptance of the filing and its assigned action date settle whether the November sell-off overshot.

The shares closed at $9.12 on 12 November 2026. That is 42.5% below the 52-week intraday high of $15.87 set on 9 September 2026, and 32.2% lower than the $13.45 close on 14 August 2026. The 3 November 2026 results release said the final submission would come within two weeks. The company finished in six days, per Drug Discovery Trends. The FDA had not publicly confirmed acceptance as of 9 November 2026.

The shares fell 27.3% on 2 November 2026 after reports that Usona Institute, a non-profit, had completed its own psilocybin NDA for major depressive disorder. Usona also holds a Commissioner's National Priority Voucher, per Drug Discovery Trends. Since the low close of $7.81 on 5 November 2026, the shares have recovered to a range of $9.12 to $9.30 across the four sessions from 9 November to 12 November 2026.

Bullish and bearish views on COMPASS Pathways Plc

The bull case on COMPASS Pathways Plc (CMPS), in brief: the filing is complete and ahead of schedule. The bear case: a rival with a voucher is filing too.

Bull case

• The filing is complete and ahead of schedule. Compass announced NDA completion on 9 November 2026, built on two Phase 3 trials (COMP005, COMP006) and a Phase 2b study, per Drug Discovery Trends. COMP360 has Breakthrough Therapy designation.
• The review clock is short by design. The voucher programme targets a review of one to two months after final submission, against 10 to 12 months normally, per Drug Discovery Trends. Management guides to a launch in the first half of 2027, subject to approval.
• Cash funds operations into 2028. The company reported $444.0 million of cash and equivalents and $51.0 million of debt at 30 September 2026 in its 3 November 2026 results release, and guides funding into 2028.
• Analysts defended the shares after the drop. RBC Capital Markets maintained a Buy rating on 10 November 2026, per company news headlines. BioSpace reported on 9 November 2026 that RBC called the sell-off a buying opportunity and that Stifel called the confirmation of imminent NDA completion reassuring. BTIG reiterated Buy with a $25 target on 3 November 2026.
• The data come from a harder population. Stifel said COMP360's data are drawn from a highly refractory treatment-resistant group, which it sees as differentiated from Usona's broader depression filing, per BioSpace on 9 November 2026.

Bear case

• A rival with a voucher is filing too. Usona's reported NDA carries the same one-to-two-month review target. Usona declined to comment on the report, per Drug Discovery Trends on 9 November 2026, and its Phase 3 depression data have not been disclosed, per BioSpace.
• Price targets are moving toward the price. Wells Fargo kept Equal-Weight and lowered its target to $10 on 4 November 2026, per company news headlines. That is $0.88 above the $9.12 close of 12 November 2026. BTIG's $25 target and HC Wainwright's $65 target, reported in the same headlines, sit far above it.
• The share count keeps rising. Ordinary shares outstanding reached 141,684,353 at 30 September 2026, from 135,722,306 at 30 June 2026 and 96,085,785 at 31 December 2025, per the company's results releases. An automatic registration statement has been on file since 5 August 2026.
• Spending is rising toward launch. Third-quarter selling, general and administrative expense was $33.0 million, against research and development of $23.5 million. The $9.8 million third-quarter net loss included a $40.8 million non-cash warrant fair-value gain; the nine-month net loss was $172.4 million.
• Approval does not open the market. Psilocybin remains a Schedule I substance. Management said on 22 September 2026 that Drug Enforcement Administration (DEA) rescheduling could take 1 to 90 days after approval, and state rules can limit where the drug is available.

Price setup

The shares closed at $9.12 on 12 November 2026, below the 50-day average of $11.98 and the 200-day average of $10.48 (adjusted daily closes). The three-month change is –32.2%.

The sequence of closes shows a V-shaped recovery inside the sell-off: $7.81 on 5 November 2026, $8.61 on 6 November 2026, $9.18 on 9 November 2026, $9.25 on 10 November 2026, $9.30 on 11 November 2026 and $9.12 on 12 November 2026. The 52-week closing low is $4.94 on 2 December 2025, and the 52-week intraday high is $15.87 on 9 September 2026.

The market has priced in a lasting competitive hit and some dilution: the shares closed 32.2% below their 14 August 2026 level while the company hit its filing timetable. The next fact that changes this is the FDA's acceptance letter and the action date attached to it. Share issuance remains available under the August registration statement, and the share count rose in each of the last two quarters.

Catalysts ahead

• ~9 December 2026 (est.): Possible FDA confirmation that the COMP360 NDA is accepted for review, with an assigned action date. An action date inside the one-to-two-month voucher target would confirm the fast clock; a later date or a refuse-to-file letter would break the case.
• Q4 2026 (date unannounced): Topline Phase 3 APPROACH results for Helus Pharma's HLP003 in major depressive disorder. A competing psychedelic readout shapes how the market weighs Compass's lead in treatment-resistant depression.
• ~9 January 2027 (est.): FDA action on COMP360, if the one-to-two-month voucher target from 9 November 2026 is met. Approval would start the DEA rescheduling clock of 1 to 90 days that management cited on 22 September 2026; a delay would push the first-half 2027 launch guide.

What would change the view

A daily close below $9.00, which would put the shares under the $9.01 post-earnings price BioSpace reported on 3 November 2026 and show the market rejecting the post-filing recovery. A refuse-to-file letter, a clinical hold or an FDA action date well beyond two months from 9 November 2026 would also break the case.

The risks this note tracks, each with what would confirm it:

• Usona Institute's reported psilocybin NDA also carries a priority voucher, so two psilocybin applications may compete for FDA attention and for the market's. Confirmed by: FDA acceptance or approval of Usona's application ahead of Compass's, or a label that favours the broader depression population.
• FDA review runs beyond the one-to-two-month target, ends in a refuse-to-file letter, or yields a restrictive label. Confirmed by: an assigned action date well beyond two months from 9 November 2026, or an 8-K disclosing adverse FDA correspondence.
• Equity issuance dilutes holders; ordinary shares rose to 141,684,353 at 30 September 2026 and an automatic registration statement has been on file since 5 August 2026. Confirmed by: a priced offering or at-the-market prospectus supplement, or a share count above 141,684,353 at the next quarterly report.
• DEA and state action lag approval, delaying commercial dispensing. Confirmed by: no DEA scheduling action within 90 days of approval, the outer bound management cited on 22 September 2026.
• Analyst targets keep falling toward the price after Wells Fargo cut to $10. Confirmed by: further target cuts or downgrades from covering firms after the 9 November 2026 filing.

What it trades with

CMPS trades on its own regulatory path more than on sector flows. The 27.3% drop on 2 November 2026 followed a single competitor report. Other psychedelic developers named in Drug Discovery Trends coverage are Definium Therapeutics (formerly MindMed), Helus Pharma (formerly Cybin), GH Research and AtaiBeckley. Their trial readouts and filings can move CMPS in sympathy. The 29 October 2026 Marijuana Moment report on a bill to overhaul federal drug classification points to the same DEA scheduling process that Compass's launch depends on.